跳至主要内容
临床试验/NCT00104429
NCT00104429终止2 期

A PhaseIIb, 96 Week, Randomised, Partially Double-blinded, Multicentre, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of GW873140 in Combination With COMBIVIR (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

ViiV Healthcare52 个研究点 分布在 9 个国家目标入组 125 人开始时间: 2005年1月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
125
试验地点
52
主要终点
Proportion of subjects with viral loads <400 copies/mL remaining on randomized treatment through Week 12

研究概览

简要总结

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.

详细描述

A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with Combivir (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Proportion of subjects with viral loads <400 copies/mL remaining on randomized treatment through Week 12

次要结局

  • - Comparison of safety and tolerability of different dosage regimens of GW873140 plus Combivir to standard of care regimen. - Assessment of drug resistance over time. - Co-receptor tropism following virological failure.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (52)

Loading locations...

相似试验